Search Results - varghese+john

17 Results

Sort By:

Interactive Systems and Methods for Identifying Target Proteins in Drug Discovery (Case No. 2025-098)

Summary: UCLA researchers from the Department of Electrical and Computer Engineering have developed a novel computational system for target protein identification, enabling integrative drug discovery. Background: Target identification (Target ID) in drug discovery involves the identification and evaluation of protein candidates that could interact...

Published: 10/1/2025 | Inventor(s): Xiang Chen, Youngseung Jeon, Christopher Hwang, Ziwen Li, Jesus Campagna, Varghese John, Whitaker Cohn, Eunice Jun

Keywords(s): AI-driven drug discovery, Alzheimer’s disease target discovery, Bioinformatics software platform, Drug, Drug Discovery, Functional annotation of proteins, High-throughput docking, large language models (LLMs), Ligand-protein docking, Mechanism-of-action prediction, Molecular docking simulation, Multi-criteria decision support, Neurodegenerative disease therapeutics, Pathway-centric drug targeting, personalized medicine, PPI-Comparator, PPI-Explorer, Protein structure prediction, Protein-protein interaction (PPI) analysis, Rational drug design, Retrieval-augmented generation (RAG), Semantic similarity modeling, Small molecule screening, Systems biology interface, Target identification (Target ID), Therapeutic impact modeling, User-guided AI exploration

Category(s): Software & Algorithms, Software & Algorithms > AI Algorithms, Software & Algorithms > Artificial Intelligence & Machine Learning, Software & Algorithms > Digital Health, Life Science Research Tools, Life Science Research Tools > Research Methods, Platforms, Platforms > Drug Delivery

Small molecule sAPPalpha enhancers that inhibit brain p-Tau as a therapeutic for Alzheimer’s Disease (UCLA Case No. 2025-163)

Contact UCLA Technology Development Group to learn more.

Published: 9/18/2025 | Inventor(s): Varghese John, Dongwook Wi, Jesus Campagna

Keywords(s):

Category(s): Therapeutics > CNS and Neurology

Novel MARK4 Inhibitors for Neurodegenerative Disorders (UCLA Case No. 2021-321)

UCLA researchers in the Department of Neurology have developed highly selective inhibitors of MARK4, aiming to revolutionize the treatment landscape for cancer and neurodegenerative disease through precise molecular targeting. BACKGROUND: MARK4 (Microtubule Affinity-Regulating Kinase 4) is a serine/threonine kinase from the AMP-activated protein...

Published: 9/10/2025 | Inventor(s): Varghese John, Jason Hinman, Jesus Campagna

Keywords(s):

Category(s): Therapeutics > CNS and Neurology

Small Molecule Enhancers of Secreted Clusterin (sCLU) as Novel Therapeutics for Alzheimer's Disease (UCLA Case No. 2024-016)

UCLA researchers from the Department of Neurology have identified and synthesized novel small molecules that enhance the levels of secreted clusterin protein, a protein that can targets a significant risk factor for the disease, and offering promising potential for the treatment of Alzheimer’s disease. BACKGROUND: Alzheimer’s disease (AD)...

Published: 7/17/2025 | Inventor(s): Varghese John

Keywords(s):

Category(s): Therapeutics > CNS and Neurology, Therapeutics > Stem Cells And Regenerative Medicine

Synthetic Exosomes (SE) for CNS Delivery of CRISPR for Gene Editing in Brain Disorders (UCLA Case No. 2021-363)

UCLA researchers from the Department of Neurology have developed synthetic exosomes, a novel delivery technology capable of transporting gene-editing tools and therapeutics across the blood-brain barrier, with successful applications in repairing Alzheimer’s-related mutations and delivering proteins, antibodies, and drugs. BACKGROUND: The emergence...

Published: 7/17/2025 | Inventor(s): Varghese John

Keywords(s): Alzheimers disease, CRISPR, delivery system, exosome, Nanotechnology, nanovesicles, synthetic biology

Category(s): Life Science Research Tools > Microfluidics And Mems, Materials > Nanotechnology, Platforms > Drug Delivery, Therapeutics > Gene Therapy And Editing, Therapeutics > CNS and Neurology

Salivary Exosome (NSEV) Analysis to Elucidate Intercellular Signaling Events that Precede Pilot Fatigue (UCLA Case No. 2021-172)

Researchers at UCLA’s Department of Neurology and Drug Discovery Lab have identified a novel set of biomarkers that change based on levels of Cognitive Fatigue (CF). These biomarkers can be used to non-invasively predict and assess levels of cognitive fatigue. BACKGROUND: Cognitive fatigue (CF) is an important factor in the efficiency and safety...

Published: 7/17/2025 | Inventor(s): Bruce Teter, Whitaker Cohn, Varghese John

Keywords(s): biomarkers, cognitive fatigue, exosome, noninvasive, non-invasive

Category(s): Diagnostic Markers > Targets And Assays

Small Molecule Humanin Mimetics and Enhancers That Normalize Neuronal p-AKT as Novel Therapeutics for Alzheimer's Disease (UCLA Case No. 2023-230)

UCLA researchers in the Department of Neurology have discovered novel small molecule humanin mimetics for the treatment of Alzheimer's disease and other chronic conditions with dysregulated p-Akt. BACKGROUND: Alzheimer’s disease (AD) is the most common form of dementia accounting for 60-70% of all cases. Nearly 7 million Americans are living...

Published: 7/17/2025 | Inventor(s): Varghese John

Keywords(s): Alzheimers disease, Cardiovascular, Cardiovascular Disease, Dementia, diabetes, mimetics, pAKT signaling, small molecules

Category(s): Therapeutics > CNS and Neurology, Therapeutics > Cardiovascular

2021-241: Enhancers of Brain Gamma Oscillations for Treatment of Neurological Disorders

SUMMARY: UCLA researchers in the Department of Neurology have developed a novel small molecule to improve native gamma oscillations as a treatment for cognitive decline in various neurological disorders. BACKGROUND: Neural circuits are facilitated by brain oscillations or rhythmic electric activity at distinct frequencies. These frequency variations...

Published: 7/17/2025 | Inventor(s): Varghese John, Istvan Mody, Jesus Campagna, Barbara Jagodzinska, Xiaofei Wei

Keywords(s):

Category(s): Therapeutics > CNS and Neurology, Therapeutics > Psychiatry And Mental Health

Novel Compounds Targeting APOE4 That Enhance Brain SIRT1 Levels and Target Novel Mechanism of Action (UCLA Cases 2020-832, 2025-277)

Researchers at UCLA's Drug Discovery Lab and Department of Chemistry have developed new chemical entity (NCE) analogs of A03, which together form a new class of compounds that target apolipoprotein E4 (ApoE4)-mediated deficits in the tau deacetylase enzyme, sirtuin 1 (SirT1). These NCEs provide an opportunity for novel therapeutic development in Alzheimer's...

Published: 9/18/2025 | Inventor(s): Varghese John, Jesus Campagna, Michael Jung

Keywords(s): Brain

Category(s): Therapeutics

2020-408: sAPPalpha Targeted Therapeutics for Alzheimer’s Disease

UCLA researchers from the Department of Neurology have developed a novel application of two compounds that target the upstream formation of toxic amyloid-beta oligomers for the effective treatment of Alzheimer’s disease. BACKGROUND: Alzheimer’s Disease (AD) is the most common age-related neurodegenerative disorder currently affecting ~6...

Published: 7/17/2025 | Inventor(s): Varghese John, Sujyoti Chandra

Keywords(s): Chemical, Cns, Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > CNS and Neurology

1 2